Monday, May 15, 2017 10:20:20 PM
ADMP...Adamis Is a Dark Horse Trotting to Win in the EpiPen Arena
http://www.investopedia.com/investing/betting-adamis-pharmaceuticals-and-ocular-therapeutix-ahead-fda-decisions-admp-ocul/?partner=YahooSA&yptr=yahoo
Adamis has a vision for its Epinephrine Pre-filled Syringe “PFS," which is designed as a cost-friendly alternative for those suffering from anaphylactic reactions. The drug maker hopes to compete with the likes of Mylan's EpiPen that has been raking in billions.
With the FDA's decision expected on June 15, Maxim analyst Jason Kolbert seems to not be concerned by the Complete Response Letter the company received from the regulator last year. While the FDA expressed concerns and pushed the firm to work on expansion of the human factors study, Adamis has since handled these challenges successfully. The expansion was just a "low hurdle" to the analyst, as he does not see this to be a meaningful roadblock in any way to Adamis' success.
The analyst is also excited about the market opportunity the company is pursuing, noting, [color=blue]"We see a billion dollar market, and in Adamis PFS a superior product [...] If Adamis can acquire just 10% market share and generate sales approaching $100M (which we believe is the low end), it suggests shares are undervalued."[/color]
Ultimately, Kolbert believes Adamis' valuation is compelling: "At a sub-$100M market capitalization and with what we believe should be the next version of an EpiPen-like product (PFS), plus a pipeline of respiratory products and compounding pharmacy revenues set to build, we see Adamis as poised for a breakout year in 2017."
As such, the analyst reiterates a Buy rating on Adamis shares, with a $10.00 price target, which implies 185% potential upside from current levels.
Daily
60minute
http://www.investopedia.com/investing/betting-adamis-pharmaceuticals-and-ocular-therapeutix-ahead-fda-decisions-admp-ocul/?partner=YahooSA&yptr=yahoo
Adamis has a vision for its Epinephrine Pre-filled Syringe “PFS," which is designed as a cost-friendly alternative for those suffering from anaphylactic reactions. The drug maker hopes to compete with the likes of Mylan's EpiPen that has been raking in billions.
With the FDA's decision expected on June 15, Maxim analyst Jason Kolbert seems to not be concerned by the Complete Response Letter the company received from the regulator last year. While the FDA expressed concerns and pushed the firm to work on expansion of the human factors study, Adamis has since handled these challenges successfully. The expansion was just a "low hurdle" to the analyst, as he does not see this to be a meaningful roadblock in any way to Adamis' success.
The analyst is also excited about the market opportunity the company is pursuing, noting, [color=blue]"We see a billion dollar market, and in Adamis PFS a superior product [...] If Adamis can acquire just 10% market share and generate sales approaching $100M (which we believe is the low end), it suggests shares are undervalued."[/color]
Ultimately, Kolbert believes Adamis' valuation is compelling: "At a sub-$100M market capitalization and with what we believe should be the next version of an EpiPen-like product (PFS), plus a pipeline of respiratory products and compounding pharmacy revenues set to build, we see Adamis as poised for a breakout year in 2017."
As such, the analyst reiterates a Buy rating on Adamis shares, with a $10.00 price target, which implies 185% potential upside from current levels.
Daily
60minute
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
